Narrow Your Results

Strategy

Sections

Showing 1 - 4 of 4 Results for "treatment"

Results

Women Who Use Drugs and Female Partners of Men Who Use Drugs Gap
HIV prevention information and confidential services are needed for PWID receiving treatment for substance use. Increased skills training for HIV disclosure to sexual partners is needed. Despite high numbers of PWID who are HIV-positive, no HIV nor drug prevention programs focus on PWID. No national guidelines exist for drug treatment.
Women Who Use Drugs and Female Partners of Men Who Use Drugs
1 study
Efforts are needed to eliminate compulsory drug detention and instead, provide PWID with HIV prevention and testing services and effective drug dependency treatment by medical professionals. Detention centers are administered by police, military or other national government public security authorities and operate outside the form criminal justice system with detainees held without trial or right of appeal and those detained do not allow people to leave voluntarily (Wolfe, 2012). Studies found that women who use drugs were not given reproductive health services, including PMTCT services in compulsory detention and/or prison settings. Detoxification programs were substandard and ineffective. Despite high rates of HIV, antiretroviral treatment is largely unavailable in compulsory drug detention centers. One study found high rates of injecting drug use within prison and high rates of syringe sharing within prisons plus incarceration was not associated with reduction in drug use, with over a quarter of these female drug users. PWID in and out of prison who have started antiretroviral treatment should be able to continue treatment with access to medical supervision. Treatment in compulsory drug detention takes the form of sanction rather than therapy, with high relapse rates.
Women Who Use Drugs and Female Partners of Men Who Use Drugs
1 study
Interventions are needed to inform women who use drugs of harm reduction early in pregnancy and to ensure systematic access to opioid agonist treatment during pregnancy and in hospitals for birth and postpartum. Some studies have shown increased risk adverse health impacts as well as of vertical transmission among women who use drugs which may be mitigated by harm reduction [See %{s:45}]
Women Who Use Drugs and Female Partners of Men Who Use Drugs
1 study
Interventions are needed to scale up and increase access to methadone and buprenorphine—effective agonist therapy for the treatment of drug dependence, as well as needle exchange/distribution programs. Studies found only tiny fractions of those who need maintenance medication had access. A study found that user fees for methadone maintenance programs presented a barrier to access to care. In places where no needle exchange programs are operating, high rates of borrowing of used syringes occur, placing IDUs at high risk of acquiring HIV.
Women Who Use Drugs and Female Partners of Men Who Use Drugs
1 study